Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avacta GroupAVCTF 13 EV-to-EBITDA is -11.34 as of Jul. 16, 2026. GuruFocus rates AVCTF with a GF Score™ of 13/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 395 Biotechnology companies, Avacta Group ranks worse than 253164.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avacta Group's enterprise value is $424.23 Mil.
Avacta Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-37.42 Mil. Therefore, Avacta Group's EV-to-EBITDA for today is -11.34.
The historical rank and industry rank for Avacta Group's EV-to-EBITDA or its related term are showing as below:
AVCTF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -198.81 Med: -8.99 Max: -0.7
Current: -11.48
During the past 13 years, the highest EV-to-EBITDA of Avacta Group was -0.70. The lowest was -198.81. And the median was -8.99.
AVCTF's EV-to-EBITDA is ranked worse than 100% of 395
companies
in the Biotechnology industry
Industry Median: 13
vs AVCTF: -11.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Avacta Group (OTCPK:AVCTF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avacta Group's PE Ratio (TTM) for today is calculated as:
Avacta Group's share price for today is $1.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Avacta Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVCTF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Avacta Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Avacta Group's EV-to-EBITDA falls into.
Avacta Group's current Enterprise Value is $424.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-37.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a EV-to-EBITDA of -11.34 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avacta Group. According to the industry distribution chart, Avacta Group ranks #999999 out of 395 companies in the Biotechnology industry.
Is Avacta Group's EV-to-EBITDA too high?
Avacta Group's current EV-to-EBITDA is -11.34. Based on the distribution chart, Avacta Group ranks #999999 out of 395 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #999999 out of 395 companies for EV-to-EBITDA. This places Avacta Group in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.00, based on 395 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avacta Group. For the Biotechnology industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current EV-to-EBITDA is -11.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $1.00 — trading 53.8% above its estimated fair value. The current EV-to-EBITDA is -11.34. Avacta Group's overall GF Score™ is 13/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Avacta Group (AVCTF), the current EV-to-EBITDA is -11.34 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $1.00 is trading 53.8% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
EV-to-EBITDA: -11.34
GF Value™: $0.65 vs. price of $1.00 (53.8% above fair value)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score
Get the complete analysis for AVCTF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
